Belsomra
From Proteopedia
(Difference between revisions)
Line 5: | Line 5: | ||
== Structural Highlights == | == Structural Highlights == | ||
- | Belsomra assumes a conformation similar to that of a horseshoe when binding to either of the two orexin receptors. Through steric hindrance, this horseshoe conformation halts transmembrane domain movement by making contact with the alpha-helices of all transmembrane domains except for the first one upon entering the binding site of the receptor. <ref> doi: 10.1038/nature14035 </ref>. Types of interactions between Belsomra and both orexin receptor subtypes include Van Der Waals interactions, aromatic packing via the pi bonds of aromatic amino acids, and hydrogen bonding. The most significant hydrogen bond occurs between the amide of the orexin receptors’ Asn324 and an amide on Belsomra. <ref> doi: 10.1038/nature14035 </ref>. Water molecules also play a role in hydrogen bonding via formation of bridges between the Belsomra drug itself and the orexin receptors’ Asn324 and His350. <ref> doi: 10.1038/nature14035 </ref>. Structural differences of the two orexin receptors’ binding sites involve only two amino acids: receptor 1 has a serine that is a threonine in receptor 2, and an alanine in receptor 1 is a threonine in receptor 2. <ref> doi: 10.1038/nature14035 </ref>. | + | Belsomra assumes a conformation similar to that of a horseshoe when binding to either of the two orexin receptors. Through steric hindrance, this horseshoe conformation halts transmembrane domain movement by making contact with the alpha-helices of all transmembrane domains except for the first one upon entering the binding site of the receptor. <ref> doi: 10.1038/nature14035 </ref>. Types of interactions between Belsomra and both orexin receptor subtypes include Van Der Waals interactions, aromatic packing via the pi bonds of aromatic amino acids, and hydrogen bonding. The most significant hydrogen bond occurs between the amide of the orexin receptors’ <scene name='74/746099/Asn324_orx2/1'>Asn324</scene> and an amide on Belsomra. <ref> doi: 10.1038/nature14035 </ref>. Water molecules also play a role in hydrogen bonding via formation of bridges between the Belsomra drug itself and the orexin receptors’ Asn324 and His350. <ref> doi: 10.1038/nature14035 </ref>. Structural differences of the two orexin receptors’ binding sites involve only two amino acids: receptor 1 has a serine that is a threonine in receptor 2, and an alanine in receptor 1 is a threonine in receptor 2. <ref> doi: 10.1038/nature14035 </ref>. |
Revision as of 00:55, 7 December 2016
|
References
- ↑ 1.0 1.1 1.2 Aschenbrenner, DS. First Orexin Receptor Antagonist Approved for Insomnia. AJN, American Journal of Nursing. 2014 Dec;114(12):26. doi: http://dx.doi.org/10.1097/01.NAJ.0000457406.61092.35.
- ↑ Stahl SM. Mechanism of action of suvorexant. CNS Spectr. 2016 Jun;21(3):215-8. doi: 10.1017/S1092852916000225. PMID:27322687 doi:http://dx.doi.org/10.1017/S1092852916000225
- ↑ 3.0 3.1 Krystal AD, Benca RM, Kilduff TS. Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system. J Clin Psychiatry. 2013;74 Suppl 1:3-20. doi: 10.4088/JCP.13011su1c. PMID:24107804 doi:http://dx.doi.org/10.4088/JCP.13011su1c
- ↑ Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998 Feb 20;92(4):573-85. PMID:9491897
- ↑ Yin J, Mobarec JC, Kolb P, Rosenbaum DM. Crystal structure of the human OX orexin receptor bound to the insomnia drug suvorexant. Nature. 2014 Dec 22. doi: 10.1038/nature14035. PMID:25533960 doi:http://dx.doi.org/10.1038/nature14035
- ↑ Yin J, Mobarec JC, Kolb P, Rosenbaum DM. Crystal structure of the human OX orexin receptor bound to the insomnia drug suvorexant. Nature. 2014 Dec 22. doi: 10.1038/nature14035. PMID:25533960 doi:http://dx.doi.org/10.1038/nature14035
- ↑ Yin J, Mobarec JC, Kolb P, Rosenbaum DM. Crystal structure of the human OX orexin receptor bound to the insomnia drug suvorexant. Nature. 2014 Dec 22. doi: 10.1038/nature14035. PMID:25533960 doi:http://dx.doi.org/10.1038/nature14035
- ↑ Yin J, Mobarec JC, Kolb P, Rosenbaum DM. Crystal structure of the human OX orexin receptor bound to the insomnia drug suvorexant. Nature. 2014 Dec 22. doi: 10.1038/nature14035. PMID:25533960 doi:http://dx.doi.org/10.1038/nature14035
- ↑ Pagel, J. F., & Parnes, B. L. (2001). Medications for the Treatment of Sleep Disorders: An Overview. Primary Care Companion to The Journal of Clinical Psychiatry, 3(3), 118–125. doi: http://dx.doi.org/10.4088/PCC.v03n0303
- ↑ Schwartz JR, Roth T. Neurophysiology of sleep and wakefulness: basic science and clinical implications. Curr Neuropharmacol. 2008 Dec;6(4):367-78. doi: 10.2174/157015908787386050. PMID:19587857 doi:http://dx.doi.org/10.2174/157015908787386050
- ↑ Sutton EL. Profile of suvorexant in the management of insomnia. Drug Des Devel Ther. 2015 Nov 11;9:6035-42. doi: 10.2147/DDDT.S73224. eCollection, 2015. PMID:26648692 doi:http://dx.doi.org/10.2147/DDDT.S73224
Proteopedia Page Contributors and Editors (what is this?)
Wil Andahazy, Lisa M Konort, Shane P. Herr, Alexander Berchansky, Nojan Jafari